Lupin launches Moxifloxacin Ophthalmic Solution
14th Feb 2020

Lupin has launched Moxifloxacin Ophthalmic Solution USP, 0.5%, for which United States Food and Drug Administration (USFDA) approval was received earlier. The product would be manufactured at Lupin's Pithampur Unit II facility, India.

Moxifloxacin Ophthalmic Solution USP, 0.5% is the AT2 rated generic equivalent of Moxeza of Novartis. It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of certain organisms. Moxifloxacin Ophthalmic Solution USP, 0.5% (RLD: Moxeza) had an annual sales of approximately $10 million in the U.S.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.